Abediterol
Abediterol (INN; development codes AZD-0548 and LAS 100977) is a once-daily experimental drug candidate for the treatment of asthma and chronic obstructive pulmonary disease (COPD). It is currently under development by the Spanish pharmaceutical company Almirall and is in Phase II clinical trials. It acts as a dual β adrenergic agonist and muscarinic antagonist and is classified as an ultra-long-acting β agonist (ultra-LABA). Its coformulation with mometasone furoate is also in Phase II clinical trials.